Humanized antibodies as potential drugs for therapeutic use.

S. Merluzzi, M. Figini, A. Colombatti, S. Canevari, C. Pucillo

Research output: Contribution to journalArticlepeer-review


Antibodies have been used therapeutically to treat a variety of clinical conditions. The introduction of monoclonal antibodies (mAb) and, recently, engineered antibodies has greatly refined and expanded the therapeutic potential of this modality of treatment. Expanded use will depend on improvement in their efficacy (affinity and specificity), demonstration of their safety, and reduction of their immunogenicity depending on the size, suboptimal biodistribution and pharmacokinetics. To surmount these problems the molecules have to be redesigned and the basic issues of how monoclonal antibodies kill cells reinvestigated. The review will survey the literature for humanized antibodies in clinical trials and the perspective of the use of mAbs or engineered antibodies in clinical practice.

Original languageEnglish
Pages (from-to)77-85
Number of pages9
JournalAdvances in clinical pathology : the official journal of Adriatic Society of Pathology
Issue number2
Publication statusPublished - 2000


Dive into the research topics of 'Humanized antibodies as potential drugs for therapeutic use.'. Together they form a unique fingerprint.

Cite this